| ◆英語タイトル：Global Bone Cancer Treatment Market Size study & Forecast, by Type (Osteosarcoma, Chondrosarcoma, Ewing Sarcoma,), by Drug Type (Immunotherapy and Targeted Therapy, Chemotherapy), by Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FE0105
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年2月8日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医薬品
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社は、2021年に約12億ドルであった世界の骨がん治療薬市場規模は、2022年から2029年の間にCAGR 4.5％増加すると予想しています。本書は、骨がん治療薬の世界市場について調査・分析を行い、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、種類別（骨肉腫、軟骨肉腫、ユーイング肉腫）分析、薬物種類別（免疫・標的療法薬、化学療法薬）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの内容をまとめています。また、本書で記載されている企業情報には、Advaxis Inc.、Takeda Pharmaceutical Company Limited、Cancervax, Inc、Cellectar Biosciences, Inc、Pfizer, Inc、Isofol Medical Ab、Gradalis Inc、Hikma Pharmaceutical PLC、QSAM Biosciences, Inc.、Zentalis Pharmaceuticalsなどが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界骨がん治療薬市場規模：種類別
- 骨肉腫の市場規模
- 軟骨肉腫の市場規模
- ユーイング肉腫の市場規模
・世界骨がん治療薬市場規模：薬物種類別
- 免疫・標的療法薬の市場規模
- 化学療法薬の市場規模
・世界骨がん治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の骨がん治療薬市場規模：地域別
- 北米の骨がん治療薬市場
- ヨーロッパの骨がん治療薬市場
- アジア太平洋の骨がん治療薬市場
- 中南米の骨がん治療薬市場
- その他地域の骨がん治療薬市場
・競争分析
・調査プロセス |
Global Bone Cancer Treatment Market is valued at approximately USD 1.2 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2022-2029. Bone Cancer is a rare disease that affects bones. It begins with bones and can spread to other parts of the body and damages normal bone tissues. Osteosarcoma is considered the most common type of bone cancer that develops in the cells where new bone tissue forms. There are different treatment methods for bone cancer which include surgery, radiation therapy and chemotherapy. The increasing prevalence of bone cancer and growing penetration of cancer care services in developing regions as well as strategic initiatives from leading market players are key factors accelerating the market growth.
The increasing incidences of bone cancers are contributing to the growth of the Global Bone Cancer Treatment Market. For instance, according to American Cancer Society’s estimates- in 2022, around 3910 new cases of bone cancer were reported in the United States, whereas approximately 2100 children & adults lost their lives due to bone cancer. Moreover, the most prevalent types of cancer in children and teens are Osteosarcoma with 56% prevalence, followed by Ewing tumors (34%), and Chondrosarcoma (6%). Also, growing government initiatives & reimbursement policies and rising healthcare infrastructure in developing regions would create a lucrative growth prospectus for the market over the forecast period. However, high treatment cost stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Bone Cancer Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of leading market players and increasing technological advancements in bone cancer treatment in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, increasing government spending on healthcare infrastructure and rising emergence of cancer care centers in the region.
Major market players included in this report are:
Advaxis Inc.
Takeda Pharmaceutical Company Limited
Cancervax, Inc
Cellectar Biosciences, Inc
Pfizer, Inc
Isofol Medical Ab
Gradalis Inc
Hikma Pharmaceutical PLC
QSAM Biosciences, Inc.
Zentalis Pharmaceuticals
Recent Developments in the Market:
In February 2022, CTI BioPharma Corp (CTIC.O) received approval for its drug for treating adult patients with bone marrow cancer from the U.S. Food and Drug Administration. Moreover, the new drug Vonjo (pacritinib), belongs to a class of anti-inflammatory treatments known as JAK inhibitors.
Global Bone Cancer Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Drug Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type
Osteosarcoma
Chondrosarcoma
Ewing Sarcoma
By Drug Type
Immunotherapy and Targeted Therapy
Chemotherapy
By Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Bone Cancer Treatment Market, by Region, 2019-2029 (USD Billion)
1.2.2. Bone Cancer Treatment Market, by Type, 2019-2029 (USD Billion)
1.2.3. Bone Cancer Treatment Market, by Drug Type, 2019-2029 (USD Billion)
1.2.4. Bone Cancer Treatment Market, by Distribution Channel, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Bone Cancer Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Bone Cancer Treatment Market Dynamics
3.1. Bone Cancer Treatment Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of bone cancer
3.1.1.2. Growing penetration of cancer care services in developing regions
3.1.1.3. Strategic initiatives from leading market players
3.1.2. Market Challenges
3.1.2.1. High Cost of Bone Cancer Treatment
3.1.3. Market Opportunities
3.1.3.1. Favourable government initiatives & reimbursement policies
3.1.3.2. Rising healthcare infrastructure in developing regions
Chapter 4. Global Bone Cancer Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Bone Cancer Treatment Market, by Type
6.1. Market Snapshot
6.2. Global Bone Cancer Treatment Market by Type, Performance – Potential Analysis
6.3. Global Bone Cancer Treatment Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Bone Cancer Treatment Market, Sub Segment Analysis
6.4.1. Osteosarcoma
6.4.2. Chondrosarcoma
6.4.3. Ewing Sarcoma
Chapter 7. Global Bone Cancer Treatment Market, by Drug Type
7.1. Market Snapshot
7.2. Global Bone Cancer Treatment Market by Drug Type, Performance – Potential Analysis
7.3. Global Bone Cancer Treatment Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
7.4. Bone Cancer Treatment Market, Sub Segment Analysis
7.4.1. Immunotherapy and Targeted Therapy
7.4.2. Chemotherapy
Chapter 8. Global Bone Cancer Treatment Market, by Distribution Channel
8.1. Market Snapshot
8.2. Global Bone Cancer Treatment Market by Distribution Channel, Performance – Potential Analysis
8.3. Global Bone Cancer Treatment Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
8.4. Bone Cancer Treatment Market, Sub Segment Analysis
8.4.1. Hospital Pharmacies
8.4.2. Drug Stores and Retail Pharmacies
8.4.3. Online Pharmacies
Chapter 9. Global Bone Cancer Treatment Market, Regional Analysis
9.1. Bone Cancer Treatment Market, Regional Market Snapshot
9.2. North America Bone Cancer Treatment Market
9.2.1. U.S. Bone Cancer Treatment Market
9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
9.2.1.2. Drug Type breakdown estimates & forecasts, 2019-2029
9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Bone Cancer Treatment Market
9.3. Europe Bone Cancer Treatment Market Snapshot
9.3.1. U.K. Bone Cancer Treatment Market
9.3.2. Germany Bone Cancer Treatment Market
9.3.3. France Bone Cancer Treatment Market
9.3.4. Spain Bone Cancer Treatment Market
9.3.5. Italy Bone Cancer Treatment Market
9.3.6. Rest of Europe Bone Cancer Treatment Market
9.4. Asia-Pacific Bone Cancer Treatment Market Snapshot
9.4.1. China Bone Cancer Treatment Market
9.4.2. India Bone Cancer Treatment Market
9.4.3. Japan Bone Cancer Treatment Market
9.4.4. Australia Bone Cancer Treatment Market
9.4.5. South Korea Bone Cancer Treatment Market
9.4.6. Rest of Asia Pacific Bone Cancer Treatment Market
9.5. Latin America Bone Cancer Treatment Market Snapshot
9.5.1. Brazil Bone Cancer Treatment Market
9.5.2. Mexico Bone Cancer Treatment Market
9.5.3. Rest of Latin America Bone Cancer Treatment Market
9.6. Rest of The World Bone Cancer Treatment Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Advaxis Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Takeda Pharmaceutical Company Limited
10.2.3. Cancervax, Inc
10.2.4. Cellectar Biosciences, Inc
10.2.5. Pfizer, Inc
10.2.6. Isofol Medical Ab
10.2.7. Gradalis Inc
10.2.8. Hikma Pharmaceutical PLC
10.2.9. QSAM Biosciences, Inc.
10.2.10. Zentalis Pharmaceuticals
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer